UY31402A1 - "piperazino-dihidrotienopirimidinas sustituidas en heterociclo" - Google Patents

"piperazino-dihidrotienopirimidinas sustituidas en heterociclo"

Info

Publication number
UY31402A1
UY31402A1 UY31402A UY31402A UY31402A1 UY 31402 A1 UY31402 A1 UY 31402A1 UY 31402 A UY31402 A UY 31402A UY 31402 A UY31402 A UY 31402A UY 31402 A1 UY31402 A1 UY 31402A1
Authority
UY
Uruguay
Prior art keywords
diseases
dihidrotienopirimidinas
heterociclo
piperazino
replaced
Prior art date
Application number
UY31402A
Other languages
English (en)
Inventor
Thomas Fox
Dennis Fiegen
Rolf Goeggel
Christoph Hoenke
Domnic Martyres
Peter Nickolaus
Pascale Pouzet
Ralf Anderskewitz
Dr Dollinger Horst
Klaus Klinder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31402A1 publication Critical patent/UY31402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a nuevos dihidrotienopirimidinsulfoxidos de la formula 1, y sales farmacologicamente tolerables de los mismo, en donde X, R3, R1, y R2 son como se definieron de la Memoria y Reivindicaciones, tienen los significados mencionados en la reivindicacion 1 y composiciones farmacéuticas que contienen estos compuestos. Son utiles para le tratamiento de trastornos o enfermedades gastrointestinales o de la vías respiratorias, enfermedades inflamatorias de las articulaciones, la piel o los ojos, enfermedades del sistema nervioso periférico o central o enfermedades cancerosas
UY31402A 2007-10-19 2008-10-17 "piperazino-dihidrotienopirimidinas sustituidas en heterociclo" UY31402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118911 2007-10-19

Publications (1)

Publication Number Publication Date
UY31402A1 true UY31402A1 (es) 2009-05-29

Family

ID=39204738

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31402A UY31402A1 (es) 2007-10-19 2008-10-17 "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"

Country Status (18)

Country Link
US (2) US8637519B2 (es)
EP (1) EP2205609B1 (es)
JP (1) JP5341899B2 (es)
KR (1) KR20100075930A (es)
CN (1) CN101827853A (es)
AR (1) AR069076A1 (es)
AU (1) AU2008313742B2 (es)
BR (1) BRPI0817781A2 (es)
CA (1) CA2702524A1 (es)
CL (1) CL2008003097A1 (es)
MX (1) MX2010003346A (es)
NZ (1) NZ585348A (es)
PE (1) PE20091081A1 (es)
RU (1) RU2500681C2 (es)
TW (1) TWI445535B (es)
UY (1) UY31402A1 (es)
WO (1) WO2009050242A2 (es)
ZA (1) ZA201001621B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
KR20100095528A (ko) * 2007-10-18 2010-08-31 베링거 인겔하임 인터내셔날 게엠베하 디하이드로티에노[3,2-ｄ]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
ES2524910T3 (es) 2007-10-19 2014-12-15 Boehringer Ingelheim International Gmbh Piperidino-dihidrotienopirimidinas sustituidas
JP5341899B2 (ja) 2007-10-19 2013-11-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロ環置換ピペラジノ−ジヒドロチエノピリミジン
JP2012519159A (ja) 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する複合薬
EP2555773A1 (de) 2010-04-08 2013-02-13 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
ES2714705T3 (es) * 2013-07-10 2019-05-29 Meiji Seika Pharma Co Ltd Inhibidor de PDE4 novedoso
CN106279173A (zh) * 2015-05-29 2017-01-04 华东理工大学 蝶啶酮衍生物作为egfr抑制剂的应用
US11365204B2 (en) 2017-09-20 2022-06-21 UNION therapeutics A/S Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
BR112020003973A2 (pt) 2017-10-23 2020-09-01 Boehringer Ingelheim International Gmbh combinação de agentes ativos para o tratamento de doenças pulmonares intersticiais fibrosantes progressivas (pf-ild)
US11292799B2 (en) 2017-12-15 2022-04-05 UNION therapeutics A/S Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
JP7203846B2 (ja) 2017-12-15 2023-01-13 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
CN111712503B (zh) * 2017-12-15 2024-04-09 联合疗法公司 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN113880859B (zh) * 2021-11-16 2022-06-21 江西科技师范大学 2-芳基-4-芳甲胺基嘧啶类化合物及其应用
EP4494701A3 (en) 2021-12-09 2025-04-02 Boehringer Ingelheim International GmbH New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
EP4426307B1 (en) 2021-12-09 2025-07-02 Boehringer Ingelheim International GmbH New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
US20250326765A1 (en) * 2022-06-02 2025-10-23 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
CN117247395A (zh) * 2022-06-16 2023-12-19 武汉人福创新药物研发中心有限公司 Pde4b抑制剂
IL318673A (en) * 2022-08-09 2025-03-01 Xizang Haisco Pharmaceutical Co Ltd PDE4B inhibitor and its use
WO2024068386A1 (en) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
US20260008788A1 (en) 2022-09-29 2026-01-08 Suzhou Ark Biopharmaceutical Co., Ltd. Aza-fused ring compound, preparation method therefor, and use thereof in medicine
EP4678644A1 (en) 2023-04-13 2026-01-14 Shanghai Yidi Biotechnology Co., Ltd. Substituted dihydrothienopyrimidine compound, preparation method therefor, and use thereof
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
WO2025067168A1 (zh) * 2023-09-25 2025-04-03 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
WO2025092985A1 (zh) * 2023-11-03 2025-05-08 合肥医工医药股份有限公司 磷酸二酯酶4b抑制剂及其制备方法与用途
WO2025162289A2 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂的晶型及其在医药上的用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) * 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL122810C (es) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO58039A (es) * 1970-01-28 1975-07-15
FR2082496A5 (es) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
RO62428A (fr) * 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
DE10064994A1 (de) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
US6849638B2 (en) 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
US6587548B2 (en) * 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
MX271416B (es) * 2003-10-02 2009-10-30 Martek Biosciences Corp Produccion de altos niveles de dha en microalgas usando cantidades modificadas de cloruro y de potasio.
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
JP5389013B2 (ja) 2007-04-20 2014-01-15 グラクソ グループ リミテッド 抗菌剤としての三環式含窒素化合物
KR20100095528A (ko) * 2007-10-18 2010-08-31 베링거 인겔하임 인터내셔날 게엠베하 디하이드로티에노[3,2-ｄ]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체
ES2524910T3 (es) * 2007-10-19 2014-12-15 Boehringer Ingelheim International Gmbh Piperidino-dihidrotienopirimidinas sustituidas
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
JP5341899B2 (ja) 2007-10-19 2013-11-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロ環置換ピペラジノ−ジヒドロチエノピリミジン
EP2214673B1 (de) * 2007-10-19 2012-05-30 Boehringer Ingelheim International GmbH Phenyl-substituierte piperazino-dihydrothienopyrimidine
AU2008312055A1 (en) * 2007-10-19 2009-04-23 Astrazeneca Ab Tetrazole derivatives as modulators of metabotropic glutamate receptors (mGluRs)
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
US8796460B2 (en) 2007-10-19 2014-08-05 Mercky Sharp & Dohme Corp. Compounds for inhibiting KSP kinesin activity
JP2012519159A (ja) 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する複合薬
CA2753604A1 (en) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
WO2009050242A2 (de) 2009-04-23
ZA201001621B (en) 2010-10-27
TWI445535B (zh) 2014-07-21
US9115142B2 (en) 2015-08-25
US8637519B2 (en) 2014-01-28
CL2008003097A1 (es) 2010-01-22
NZ585348A (en) 2012-02-24
RU2500681C2 (ru) 2013-12-10
WO2009050242A3 (de) 2009-07-30
EP2205609B1 (de) 2017-03-29
PE20091081A1 (es) 2009-08-24
TW200918073A (en) 2009-05-01
US20140107103A1 (en) 2014-04-17
AU2008313742B2 (en) 2013-11-28
MX2010003346A (es) 2010-04-09
JP5341899B2 (ja) 2013-11-13
JP2011500639A (ja) 2011-01-06
US20100305102A1 (en) 2010-12-02
BRPI0817781A2 (pt) 2019-09-24
EP2205609A2 (de) 2010-07-14
RU2010119645A (ru) 2012-01-27
AU2008313742A1 (en) 2009-04-23
KR20100075930A (ko) 2010-07-05
AR069076A1 (es) 2009-12-30
CN101827853A (zh) 2010-09-08
CA2702524A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
UY31402A1 (es) "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
UY30287A1 (es) Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
BRPI0608387A2 (pt) compostos para o tratamento de doenças inflamatórias
CR20120002A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
PA8585001A1 (es) Compuestos de tiazol para el tratamiento de transtornos neurodegenerativos
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
GT200900333A (es) Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.
ECSP10010230A (es) Derivados de isoxazolo-piridina
BR112014026176A2 (pt) dipiridilaminas substituídas e usos das mesmas
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CO6541528A2 (es) Derivados de la cromenona
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
UY31243A1 (es) Compuestos de 2-aza-biciclo[2.2.2]octano y usos para los mismos
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
UY31326A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171017